Renalogic, a leading provider of healthcare solutions for self-funded plans and their members dealing with chronic kidney disease (CKD), has partnered with Lyfebulb, a patient empowerment platform that develops and operates the online community TransplantLyfe. The partnership aims to survey dialysis patients in order to gain valuable insights into their firsthand experiences and the challenges they face in managing this chronic illness.
The survey revealed alarming statistics. 62% of dialysis treatments were unplanned, highlighting the unpredictability and disruption caused by CKD. Additionally, over half (54%) of patients reported having to stop work while on dialysis, and 50% had visited the emergency room or been hospitalized in the past year.
“Dialysis patients face immense physical, emotional and logistical challenges in managing their condition,” said Kevin Weinstein, CEO of Renalogic. “By partnering with Lyfebulb to amplify the perspectives of this patient community, we aim to drive meaningful changes that enhance the dialysis experience and clinical outcomes.”
The survey is summarized in a report that covers a range of topics, including:
- Financial impact of dialysis
- The taxing physical and mental effects of dialysis
- Barriers to accessing high-quality care and support services
- Impacts on the workplace
“We were pleased to have the opportunity to partner with Renalogic on this survey to tap into our community and dig into the impact of dialysis on the patients who are undergoing treatment,” stated Karin Hehenberger, President of Lyfebulb and Chief Medical Officer of Patient Care America. “While we know that dialysis is truly life-saving and necessary for survival for many, we also know that we can do more and better for this community of those living with ESRD.”
Renalogic and Lyfebulb are dedicated to using these insights to bring about meaningful change and improve the quality of life for the dialysis community. The Dialysis Patient Experience report is accessible here.
